Published in PLoS One on February 23, 2012
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother (2012) 0.88
Optical imaging of cell death in traumatic brain injury using a heat shock protein-90 alkylator. Cell Death Dis (2013) 0.84
In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment. Clin Cancer Res (2014) 0.81
Effect of Ca²⁺ on the steady-state and time-resolved emission properties of the genetically encoded fluorescent sensor CatchER. J Phys Chem B (2014) 0.80
Molecular probes for fluorescence lifetime imaging. Bioconjug Chem (2015) 0.80
FLIM-FRET for Cancer Applications. Curr Mol Imaging (2015) 0.79
In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe. Technol Cancer Res Treat (2013) 0.78
In vivo validation of quantitative frequency domain fluorescence tomography. J Biomed Opt (2012) 0.76
Peptide-fluorescent bacteria complex as luminescent reagents for cancer diagnosis. PLoS One (2013) 0.75
Evaluation of breast tissue with confocal strip-mosaicking microscopy: a test approach emulating pathology-like examination. J Biomed Opt (2017) 0.75
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 12.85
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol (2003) 10.76
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol (2003) 4.05
Fluorescence lifetime measurements and biological imaging. Chem Rev (2010) 3.99
Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B (2009) 3.31
Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans. Opt Express (2007) 2.84
Fluorescence lifetime imaging in turbid media. Opt Lett (1996) 2.21
Whole-body fluorescence lifetime imaging of a tumor-targeted near-infrared molecular probe in mice. J Biomed Opt (2005) 2.14
Near-infrared-emissive polymersomes: self-assembled soft matter for in vivo optical imaging. Proc Natl Acad Sci U S A (2005) 2.10
Deep-tissue anatomical imaging of mice using carbon nanotube fluorophores in the second near-infrared window. Proc Natl Acad Sci U S A (2011) 2.01
The HER2 testing conundrum. Nat Biotechnol (2010) 2.00
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res (2008) 1.96
Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett (2010) 1.85
Fluorescence lifetime imaging system for in vivo studies. Mol Imaging (2007) 1.83
Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol (2002) 1.83
All-optical anatomical co-registration for molecular imaging of small animals using dynamic contrast. Nat Photonics (2007) 1.82
Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med (2010) 1.75
Imaging of fluorescent yield and lifetime from multiply scattered light reemitted from random media. Appl Opt (1997) 1.53
Near-infrared fluorescence optical imaging and tomography. Dis Markers (2004) 1.51
In vivo resolution of multiexponential decays of multiple near-infrared molecular probes by fluorescence lifetime-gated whole-body time-resolved diffuse optical imaging. Mol Imaging (2007) 1.19
Imaging targeted-agent binding in vivo with two probes. J Biomed Opt (2010) 1.17
Simple time-domain optical method for estimating the depth and concentration of a fluorescent inclusion in a turbid medium. Opt Lett (2004) 1.12
Functional optical detection based on pH dependent fluorescence lifetime. Lasers Surg Med (2004) 1.11
HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem (2010) 1.10
In vivo molecular imaging biomarkers: clinical pharmacology's new "PET"? Clin Pharmacol Ther (2007) 1.09
Cy5.5-labeled Affibody molecule for near-infrared fluorescent optical imaging of epidermal growth factor receptor positive tumors. J Biomed Opt (2010) 1.07
Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Mol Imaging (2010) 1.07
In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes. Mol Imaging Biol (2009) 0.96
Using in-vivo fluorescence imaging in personalized cancer diagnostics and therapy, an image and treat paradigm. Technol Cancer Res Treat (2011) 0.93
Fluorescence lifetime imaging of activatable target specific molecular probes. Contrast Media Mol Imaging (2010) 0.90
Evaluation of single-photon-counting measurements of excited-state lifetimes. Proc Natl Acad Sci U S A (1982) 0.90
Spectroscopically well-characterized RGD optical probe as a prerequisite for lifetime-gated tumor imaging. Mol Imaging (2011) 0.85
Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors. Breast Cancer Res (2010) 0.82
Watching a protein as it functions with 150-ps time-resolved x-ray crystallography. Science (2003) 4.12
Fluorescence lifetime measurements and biological imaging. Chem Rev (2010) 3.99
Whole-body fluorescence lifetime imaging of a tumor-targeted near-infrared molecular probe in mice. J Biomed Opt (2005) 2.14
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res (2008) 1.96
Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res (2004) 1.89
Multimodality molecular imaging with combined optical and SPECT/PET modalities. J Nucl Med (2008) 1.83
Fluorescence lifetime imaging system for in vivo studies. Mol Imaging (2007) 1.83
Time-dependent whole-body fluorescence tomography of probe bio-distributions in mice. Opt Express (2005) 1.73
Near infrared dyes as lifetime solvatochromic probes for micropolarity measurements of biological systems. Biophys J (2007) 1.71
Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem (2006) 1.71
Heptamethine cyanine dyes with a robust C-C bond at the central position of the chromophore. J Org Chem (2006) 1.68
Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol (2010) 1.66
Handheld array-based photoacoustic probe for guiding needle biopsy of sentinel lymph nodes. J Biomed Opt (2010) 1.65
Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol (2008) 1.62
Hands-free, wireless goggles for near-infrared fluorescence and real-time image-guided surgery. Surgery (2011) 1.60
In vivo fluorescence lifetime tomography. J Biomed Opt (2009) 1.55
Noninvasive photoacoustic and fluorescence sentinel lymph node identification using dye-loaded perfluorocarbon nanoparticles. ACS Nano (2010) 1.53
Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med (2012) 1.52
Direct measurement of association and dissociation rates of DNA binding in live cells by fluorescence correlation spectroscopy. Biophys J (2009) 1.52
[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 1.50
Complementary optical and nuclear imaging of caspase-3 activity using combined activatable and radio-labeled multimodality molecular probe. J Biomed Opt (2009) 1.40
Ultrafast fluorescence dynamics of tryptophan in the proteins monellin and IIAGlc. J Am Chem Soc (2006) 1.34
Optical imaging of mammary and prostate tumors in living animals using a synthetic near infrared zinc(II)-dipicolylamine probe for anionic cell surfaces. J Am Chem Soc (2010) 1.34
Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med (2009) 1.33
Synthesis and characterization of a macrocyclic near-infrared optical scaffold. J Am Chem Soc (2003) 1.33
Discovery of N-phenyl-4-(thiazol-5-yl)pyrimidin-2-amine aurora kinase inhibitors. J Med Chem (2010) 1.32
Using noninvasive multispectral imaging to quantitatively assess tissue vasculature. J Biomed Opt (2007) 1.30
Monomolecular multimodal fluorescence-radioisotope imaging agents. Bioconjug Chem (2005) 1.30
Biodegradable pH-sensing dendritic nanoprobes for near-infrared fluorescence lifetime and intensity imaging. J Am Chem Soc (2007) 1.30
Distribution of mitochondrial NADH fluorescence lifetimes: steady-state kinetics of matrix NADH interactions. Biochemistry (2005) 1.29
Cross-validating FRAP and FCS to quantify the impact of photobleaching on in vivo binding estimates. Biophys J (2010) 1.27
Near-infrared fluorescence goggle system with complementary metal-oxide-semiconductor imaging sensor and see-through display. J Biomed Opt (2013) 1.27
Real time in vivo non-invasive optical imaging using near-infrared fluorescent quantum dots. Acad Radiol (2005) 1.24
The crosstalk between EGF, IGF, and Insulin cell signaling pathways--computational and experimental analysis. BMC Syst Biol (2009) 1.24
Co-registered optical coherence tomography and fluorescence molecular imaging for simultaneous morphological and molecular imaging. Phys Med Biol (2010) 1.22
A novel approach to a bifunctional photosensitizer for tumor imaging and phototherapy. Bioconjug Chem (2005) 1.20
In vivo resolution of multiexponential decays of multiple near-infrared molecular probes by fluorescence lifetime-gated whole-body time-resolved diffuse optical imaging. Mol Imaging (2007) 1.19
Predicting in vivo fluorescence lifetime behavior of near-infrared fluorescent contrast agents using in vitro measurements. J Biomed Opt (2008) 1.18
Fluorescence lifetime properties of near-infrared cyanine dyes in relation to their structures. J Photochem Photobiol A Chem (2008) 1.16
Gold nanocages covered with thermally-responsive polymers for controlled release by high-intensity focused ultrasound. Nanoscale (2011) 1.15
(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl Med Biol (2009) 1.14
Synthesis and evaluation of polyhydroxylated near-infrared carbocyanine molecular probes. Org Lett (2004) 1.14
Ratiometric analysis of fluorescence lifetime for probing binding sites in albumin with near-infrared fluorescent molecular probes. Photochem Photobiol (2007) 1.14
Multivalent carbocyanine molecular probes: synthesis and applications. Bioconjug Chem (2005) 1.13
Activatable molecular systems using homologous near-infrared fluorescent probes for monitoring enzyme activities in vitro, in cellulo, and in vivo. Mol Pharm (2009) 1.13
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther (2008) 1.13
Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep (2010) 1.11
Rapid segmental and subdomain motions of DNA polymerase beta. J Biol Chem (2002) 1.11
Functional optical detection based on pH dependent fluorescence lifetime. Lasers Surg Med (2004) 1.11
Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a 64Cu-labeled RGD peptide. J Nucl Med (2007) 1.10
Preparation and biological evaluation of 64Cu-CB-TE2A-sst2-ANT, a somatostatin antagonist for PET imaging of somatostatin receptor-positive tumors. J Nucl Med (2008) 1.10
HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem (2010) 1.10
Video-rate fluorescence diffuse optical tomography for in vivo sentinel lymph node imaging. Biomed Opt Express (2011) 1.09
Formation of a mast cell synapse: Fc epsilon RI membrane dynamics upon binding mobile or immobilized ligands on surfaces. J Immunol (2009) 1.09
Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor. Bioconjug Chem (2007) 1.09
Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure (2003) 1.09
In vivo targeted deep-tissue photodynamic therapy based on near-infrared light triggered upconversion nanoconstruct. ACS Nano (2012) 1.08
Optimization of multiphoton excitation microscopy by total emission detection using a parabolic light reflector. J Microsc (2007) 1.08
Neutrophil elastase mediates innate host protection against Pseudomonas aeruginosa. J Immunol (2008) 1.07
Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Mol Imaging (2010) 1.07
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
Intensity profiles of linearly polarized light backscattered from skin and tissue-like phantoms. J Biomed Opt (2005) 1.05
Detection of enzyme activity in orthotopic murine breast cancer by fluorescence lifetime imaging using a fluorescence resonance energy transfer-based molecular probe. J Biomed Opt (2011) 1.05
Multiphoton microscopy with near infrared contrast agents. J Biomed Opt (2010) 1.05
DESIGN OF LIPOSOMES CONTAINING PHOTOPOLYMERIZABLE PHOSPHOLIPIDS FOR TRIGGERED RELEASE OF CONTENTS. J Therm Anal Calorim (2009) 1.04
Rational approach to select small peptide molecular probes labeled with fluorescent cyanine dyes for in vivo optical imaging. Biochemistry (2011) 1.04
Dynamic noninvasive monitoring of renal function in vivo by fluorescence lifetime imaging. J Biomed Opt (2009) 1.04
Normal tissue protection for improving radiotherapy: Where are the Gaps? Transl Cancer Res (2012) 1.03
'Image and treat': an individualized approach to urological tumors. Curr Opin Oncol (2010) 1.03
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. J Med Chem (2004) 1.02
Flow cytometric measurement of fluorescence (Förster) resonance energy transfer from cyan fluorescent protein to yellow fluorescent protein using single-laser excitation at 458 nm. Cytometry A (2003) 1.02
Near-infrared pH-activatable fluorescent probes for imaging primary and metastatic breast tumors. Bioconjug Chem (2011) 1.02
Folate-modified gold nanoclusters as near-infrared fluorescent probes for tumor imaging and therapy. Nanoscale (2012) 1.01
Design, synthesis and evaluation of near-infrared fluorescent pH indicators in a physiologically relevant range. Chem Commun (Camb) (2005) 1.01
Perspectives and potential applications of nanomedicine in breast and prostate cancer. Med Res Rev (2010) 1.00
Monitoring the biodegradation of dendritic near-infrared nanoprobes by in vivo fluorescence imaging. Mol Pharm (2009) 1.00
In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med (2011) 1.00
Radiolabeling of HER2 specific Affibody(R) molecule with F-18. J Fluor Chem (2008) 0.99
Direct curvature correction for noncontact imaging modalities applied to multispectral imaging. J Biomed Opt (2010) 0.99
Near infrared-fluorescent and magnetic resonance imaging molecular probe with high T1 relaxivity for in vivo multimodal imaging. Chem Commun (Camb) (2010) 0.99
Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol (2009) 0.98